Highest-materiality recent filing
Maximus Q3 adjusted EPS $2.22 beats $2.16 YoY; cuts FY2026 guidance on federal contract modification
Revenue $1.28B vs $1.35B prior year; diluted EPS $1.95 (adjusted $2.22) vs $1.86 ($2.16).
Maximus Q2 EPS beats estimates, raises FY2026 guidance, authorizes $400M buyback
Revenue $1.31B (vs $1.36B YoY); diluted EPS $1.80, adjusted $2.07 (vs $2.01 YoY).
Maximus Q1 adj EPS $1.85 beats prior $1.61; raises FY2026 guidance
Revenue $1.35B (-4.1% YoY), in-line with expectations; GAAP EPS $1.70 vs $0.69, adj EPS $1.85 vs $1.61.
Full year revenue $5.43B (+2.4% YoY); organic growth 3.9% driven by U.S. Federal clinical programs.
Maximus Q3 FY2025 EPS $1.86 ($2.16 adj); raises full-year guidance
Revenue $1.35B (+2.5% YoY); organic growth 4.3% led by U.S. Federal Services (11.4% growth).
Maximus Q2 FY2025: EPS $1.69 (adj. $2.01); raises FY revenue/earnings guidance
Revenue $1.36B (+1.0%); adjusted EPS $2.01 vs $1.57 YoY; organic growth 3.0%.
Maximus Q1 revenue up 5.7% to $1.40B, raises FY25 adjusted EPS guidance to $5.90-$6.20
Adjusted diluted EPS $1.61 vs $1.34 YoY; GAAP EPS $0.69 includes $38M divestiture charges from Australia/South Korea sales.
Maximus board authorizes $200M increase to stock purchase program
Previous $200M authorization (June 2024) fully consumed; $171.4M remained as of Sep 30, 2024.
CMS cancelled the CCO solicitation covering 1-800-MEDICARE and Federal Marketplace; no immediate re-solicitation planned.
Maximus FY2024 revenue up 8.2% to $5.31B; adj. EPS $6.11; FY2025 guidance $5.70-$6.00
Full year FY2024 revenue $5.31B (+8.2% YoY); diluted EPS $4.99; adjusted diluted EPS $6.11.
Maximus Q3 FY2024 revenue $1.31B (+10.6%), adj. EPS $1.74, raises FY guidance for third time
Revenue $1.31B (+10.6% YoY), diluted EPS $1.46, adjusted diluted EPS $1.74 (vs $0.50 and $0.78).
Maximus expands stock buyback program to $200M aggregate
Board authorized $200M stock purchase program, including $6M remaining from prior authorization.
Maximus Q2 revenue up 11.7% to $1.35B, adjusted EPS $1.57; raises FY24 guidance
Revenue $1.35B (+11.7% YoY); organic growth 12.6%; adjusted EPS $1.57 vs $0.81 prior year.
Maximus Q1 revenue $1.33B (+6.2%); raises FY24 EPS and FCF guidance
Revenue $1.33B (organic +6.9%); diluted EPS $1.04, adjusted EPS $1.34 vs $0.65/$0.94 YoY.
Maximus reports Q4/FY2023 results; FY2024 guidance $5.05-5.2B revenue, adj. EPS $5.05-5.35
FY2023 revenue $4.90B (+5.9% YoY), adj. diluted EPS $3.83; Q4 revenue $1.26B (+7.0%), organic growth 7.4%.
Revenue $1.19B, +5.6% YoY; organic growth 6.7% driven by U.S. segments.
Maximus reports MOVEit breach affecting 8-11M individuals; records $15M expense
Unauthorized third party exploited MOVEit zero-day; accessed personal info of 8 to 11 million individuals.
Maximus Q2 FY2023 EPS down; reaffirms FY guidance; debt reduced $275M
Q2 revenue $1.21B (+2.5% YoY); diluted EPS $0.52, adjusted EPS $0.80 (vs $0.80 and $1.07 prior year).
Maximus Q1 beats, raises FY23 guidance on restart of Medicaid redeterminations
Q1 revenue $1.25B (+8.5% YoY); organic growth 10.3%; adjusted EPS $0.94, down from $1.12.
Maximus FY22 rev $4.63B, adj EPS $4.37; FY23 rev guide $4.75-4.90B, adj EPS $3.70-4.00
FY22 revenue $4.63B, up 8.9% YoY; diluted EPS $3.29, adjusted EPS $4.37 (vs $5.19 prior year).
Maximus Q3 FY2022 revenue $1.13B, EPS $0.51; cuts FY2022 EPS guidance on $11.7M write-down
Revenue $1.13B, down $118M YoY; normalized organic growth ~21% ex COVID response work.
Maximus unveils 3-5 year strategy: mid-single-digit organic growth, 10-14% adj. op. margin
Targets $150B addressable market growing at ~6% over next 3-5 years; three growth pillars: Customer Services Digitally Enabled, Future of Health, Advanced Technologies.
Maximus Q2 rev $1.18B (+22.7%); cuts FY22 EPS guidance to $3.00-$3.50 amid PHE delays
Revenue $1.18B (+22.7% YoY); organic flat; normalized organic ~20% excluding COVID work.
Maximus Q1 rev $1.15B (+21.7%), raises FY22 rev guidance to $4.5-4.7B; adj EPS flat
Revenue $1.15B, up 21.7% YoY; COVID-19 response work $120M, down $40M YoY.
Maximus FY21 revenue $4.25B (+23%), EPS $4.67; FY22 guidance revenue $4.4-4.6B
Revenue $4.25B (+22.9% YoY) driven by $1.1B COVID-19 response work and $322.7M from Attain Federal and VES acquisitions.
Maximus reports record Q3 revenue of $1.24B, raises FY21 guidance
Revenue $1.24B (+38% YoY); GAAP EPS $1.51, adjusted EPS $1.66.
VES 2020 net revenue $364.7M, net income $52.2M (14.3% margin); 2019 net income $71.2M (20.3% margin).
On February 27, 2024, Maximus, Inc. (the “Company”) announced that Teresa A. Weipert, General Manager, U.S. Federal Services is departing the Company.
David Francis, who has served as the General Counsel of Maximus since 1998, has announced his intention to retire at the end of 2023.
Also effective December 1, 2021, Maximus appointed Theresa Golinvaux, age 47, as its Principal Accounting Officer.
the Company appointed David Mutryn as its Chief Financial Officer and Principal Financial Officer to replace Richard Nadeau.
On September 14, 2021, Peter B. Pond resigned from the Maximus board of directors.
The board of directors appointed John J. Haley as the independent, non-executive Chair to replace Mr. Pond as well as the Chair of the Compensation Committee.
In addition, director Anne K. Altman was appointed Vice Chair of the board of directors.
Maximus previously disclosed the planned retirement of its Chief Financial Officer, Richard J. Nadeau, effective November 30, 2021.
Maximus previously disclosed the retirement of Thomas Romeo from his role as U.S. Federal Services Segment General Manager effective July 31, 2021.
Max materiality 0.85 · Median 0.70 · Most common event earnings